Status:
COMPLETED
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II
Lead Sponsor:
University of Rochester
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Cancer-related Problem/Condition
Cognitive Impairment
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional i...
Detailed Description
Cancer-related cognitive dysfunction (CRCD) is a significant problem, affecting up to 75% of patients receiving chemotherapy. Older adults are at greater risk of developing CRCD which can negatively a...
Eligibility Criteria
Inclusion
- Have a diagnosis of invasive breast cancer
- Planned to receive systemic therapy for breast cancer or actively receiving systemic therapy for breast cancer with two additional cycles remaining.
- Be age 65 or older
- Able to provide informed consent
- Able to read and understand English (or possess a designated health care proxy that can do the same that was designated prior to the patient losing decision-making capabilities)
Exclusion
- Have surgery planned within 3 months of consent
- Patients who do not have decision-making capacity (decisionally or cognitively impaired) AND do NOT have a previously designated health care proxy (established prior to their cognitive impairment) available to sign consent
- Patients with breast cancer receiving endocrine therapy as their only systemic therapy will not be eligible.
Key Trial Info
Start Date :
April 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2024
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04669301
Start Date
April 2 2021
End Date
August 30 2024
Last Update
July 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rochester
Rochester, New York, United States, 14623